Trial Profile
The Effect of Intensive Urate Lowering Therapy (ULT) with Febuxostat in Comparison with Allopurinol on Cardiovascular Risk in Patients with Gout Using Surrogate Markers: a Randomized, Controlled Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Febuxostat (Primary) ; Allopurinol
- Indications Gout
- Focus Therapeutic Use
- Acronyms FORWARD
- Sponsors Menarini
- 07 Jun 2019 This trial has been completed in Croatia, according to European Clinical Trials Database.
- 01 Sep 2017 Status changed from active, no longer recruiting to completed.
- 28 Jul 2017 This study has been completed in Netherlands (End Date: 11-09-2015).